SAN RAFAEL, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today announced the pricing of an underwritten public offering of 6,000,000 total units and pre-funded units for gross proceeds of approximately $6.0 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of 3,100,000 units, priced at a public ...

Ekso Bionics (EKSO) has reached a significant milestone in terms of transforming mobility solutions, particularly for individuals with spinal cord injuries (SCI). The company recently secured initial reimbursement from the Centers for Medicare & Medicaid Services (CMS) for its Ekso Indego Personal exoskeleton. This achievement is poised to expand Ekso Bionics' foothold in the growing exoskeleton technology market, which is gaining traction in both medical and industrial sectors. Strategic Implications The C ...

Ekso Bionics CEO Scott Davis said the following in the Q2 earnings report. The bad news for Ekso Bionics starts with its diluted earnings per share of -13 cents. That's worse than the -11 cents per share Wall Street was expecting. Even if it's an improvement over the company's -31 cents per share from the same period of the year prior. "With the Medicare reimbursement mechanisms in place, we are focused on reaching a larger U.S. population of individuals living with a spinal cord injury ("SCI") and anticipa ...

Financial Data and Key Metrics Changes - Revenue for the first half of 2024 was $8.7 million, slightly down from $8.8 million in the same period of 2023 [7] - Net loss applicable to common stockholders for the first half of 2024 was $5.8 million or $0.33 per share, compared to a net loss of $8.6 million or $0.64 per share for the same period in 2023 [8] - Record quarterly sales of $5 million in Q2 2024, up from $4.7 million in Q2 2023 [45] - Gross profit for Q2 2024 was $2.6 million, with a gross margin of approximately 53%, compared to a gross profit of $2.3 million and a gross margin of 48% in Q2 2023 [45] Business Line Data and Key Metrics Changes - Sold a total of 66 EksoHealth devices in the first half of 2024, with 37 devices sold in Q2 2024 [7][17] - The performance in the EksoHealth segment was driven by growth in the Enterprise Health business, particularly the EksoNR and Ekso therapy devices [17] - Device revenue in the Industrial segment, EksoWorks, increased by approximately $150,000 from the same period a year ago [61] Market Data and Key Metrics Changes - Strong international demand, particularly in the EMEA region, driven by adoption in neurorehabilitation programs [4] - Increased interest in the Ekso Indego Personal device following CMS reimbursement decisions, with initial claims submitted [18][39] Company Strategy and Development Direction - The company is focused on expanding its market footprint through relationships with Integrated Delivery Networks (IDNs) and securing larger multiunit capital deals [40] - Plans to enhance content marketing efforts and leverage patient testimonials to drive interest and adoption of devices [5] - A scalable go-to-market strategy is being implemented to facilitate patient engagement and training for the Ekso Indego Personal [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future prospects and the potential for significant revenue growth from the Ekso Indego Personal in 2025 and beyond [34][39] - The company is committed to ensuring access to the Indego Personal for qualified individuals and is bullish on growth opportunities in the spinal cord injury community [42] - Management noted that U.S. sales were slightly affected by fluctuations in procurement cycles but maintained strong sales to individual clinics and hospitals [58] Other Important Information - Cash and restricted cash as of June 30, 2024, was $5.9 million, down from $8.6 million as of December 31, 2023 [47] - Operating expenses for Q2 2024 were $5 million, down from $6.5 million in Q2 2023, primarily due to lower general and administrative expenses [20] Q&A Session Summary Question: Where is the interest pipeline for Indego Personal materializing from? - Interest is coming from individuals with spinal cord injuries, physical therapists, clinics, and physicians [9][24] Question: Was there any drag in the quarter from Indego Personal units shipped? - No, all devices shipped in the quarter were able to recognize revenue [11] Question: How many Indego Personal units have been delivered since the CMS decision? - The company has submitted initial claims and is seeing an increase in the pipeline of inquiries [51] Question: Can you characterize the mix of inquiries from individuals versus clinics? - The mix is approximately 50-50 between individuals and clinics [68] Question: Do you expect the inquiry mix to change over time? - There is a direct correlation between marketing efforts and increased interest, suggesting potential changes in the mix [70]

Another stock from the same industry, Accelerate Diagnostics (AXDX) , has yet to report results for the quarter ended June 2024. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Ekso Bionics (EKSO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. Ekso Bionics, which belongs to the Zacks Medical - Instruments ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or Table of Contents FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 ...

Exhibit 99.1 Ekso Bionics Reports Record Quarterly Sales of $5.0 Million in Second Quarter 2024 SAN RAFAEL, Calif., July 29, 2024 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2024. 1 ● Reported revenues of $5.0 million in the second quarter of 2024 ● Initial Medicare claims for Ekso Indego Personal are currently pending ...

SAN RAFAEL, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company" or "Ekso Bionics"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2024. "We are pleased with our significant progress in the second quarter of 2024, highlighted by record sales and the announcement of Centers for Medicare & Medicaid Services' ("CMS") national Medicare pricing determination f ...

SAN RAFAEL, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2024 after the close of trading on Monday, July 29, 2024. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. A live webcast of the eve ...

Collaboration Expands Use of EksoNR and Ekso Indego Devices in Rehabilitation and Community Settings to Better Improve Patient Quality of Life SAN RAFAEL, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company" or "Ekso"), an industry leader in exoskeleton technology for medical and industrial use, today announced a research partnership with Shepherd Center, a renowned rehabilitation hospital in Atlanta, to incorporate EksoNR and Ekso Indego devices across its reha ...